We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Destiny Pharma Plc | LSE:DEST | London | Ordinary Share | GB00BDHSP575 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.00 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 2.50 | 3.50 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 3.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 13/8/2024 | 07:00 | UK RNS | AIM Cancellation - Destiny Pharma plc |
| 12/8/2024 | 07:00 | UK RNS | Destiny Pharma PLC Last Day of Dealings on AIM |
| 05/8/2024 | 11:58 | UK RNS | Destiny Pharma PLC Director/PDMR Shareholding |
| 05/8/2024 | 09:50 | ALNC |  Destiny Pharma shares fall amid XF-73 fending off MRSA in wounds |
| 05/8/2024 | 07:00 | UK RNS | Destiny Pharma PLC XF-73 prevents bacterial invasion of bloodstream |
| 31/7/2024 | 11:00 | UK RNS | Destiny Pharma PLC Result of GM and Cancellation of Trading on AIM |
| 22/7/2024 | 07:00 | UK RNS | Destiny Pharma PLC Treatment of XF-73 Nasal reduces antibiotic use |
| 15/7/2024 | 09:25 | ALNC | Destiny Pharma looks to go private to raise funds, avoid liquidation |
| 15/7/2024 | 07:00 | UK RNS | Destiny Pharma PLC Proposed Cancellation of Admission to Trading |
| 20/6/2024 | 07:00 | UK RNS | Destiny Pharma PLC Exercise of Options and Total Voting Rights |
Destiny Pharma (DEST) Share Charts1 Year Destiny Pharma Chart |
|
1 Month Destiny Pharma Chart |
Intraday Destiny Pharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 04/11/2024 | 11:31 | Destiny Pharma plc | 3,012 |
| 22/11/2022 | 12:29 | Destiny Pharma | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 28/8/2024 17:32 by carlisle44 What a snip for Sebala this might me. If sizeable Royalties are down the road (IF) why not nip them in the bud and acquire Dest...... |
Posted at 25/8/2024 09:37 by john henry Hats off for calling this correct Bones i must admit with the advance phase 3 products they had i never expected administration.im guessing pharma simply wasnt interested in the space DEST was working in. Will be interesting to see who eventually gets hold of the Tech. Thankfully no damage done, however GL to those who may have taken a hit. |
Posted at 05/7/2024 08:15 by bones698 What's the rns going to say though? I'm finding very difficult to see a way out of this for dest. The share price has been destroyed by the y poor management which now makes it almost impossible to raise without huge dillution. Their drugs are years away an da lot of money away from ever seeing then market. Looks likely to deliat if anything so either way it's pretty screwed. They have prnoisimg drugs but no way tonmonitise them an dot will take years |
Posted at 12/6/2024 20:30 by bones698 It's possible but unlikely. Keep an eye on the share price the placing price is likely 30% below where it levels off I'd they get it away at a decent price. If the have to take a bad price due to the size of the raise then yes any low single digits becomes possible. Even then I don't see a case to buy shares here it's simply to far away from success and will require a lot more fund raises and dillution to get there. Pretty much a mess this one would t even buy it on hopes of a dead cat bounce tbh. Gl anyone that takes that gamble though |
Posted at 11/6/2024 07:58 by oliversydney Very encouraging Rns today which could well move the share price as near all time low |
Posted at 26/4/2024 11:25 by edmonda "A year of progress, and addressing the future", new research note is here: Destiny Pharma (LON:DEST) full-year results for the year ending December 31 2023 included news of a strategic review of the options for its lead program XF-73 nasal. Cost-controls and reduced clinical trial spend at this point in the development of Destiny’s assets reduced the loss for the year. With the increased focus on the partnering of XF-73 nasal, we were left in no doubt after the analysts’ meeting that XF-73 nasal is both a valuable asset and that it will be partnered at some point in time. While an external out-licensing transaction for XF-73 nasal similar to that for NTCD-M3 remains probable, the strategic update suggests a range of other options to achieve the same result for this asset. Our fair value for Destiny Pharma plc has changed to £212.0m (or 234p / share) from £254.7m (or 279p / share). This reflects the longer times until Phase 3 studies start and, as a result, its products launch at Destiny’s partners. It also reflects the vast global unmet need that XF-73 nasal can address. |
Posted at 29/2/2024 13:37 by marvelman Amaretto...thanks for the heads up re post 2795. I thought I would take a look at his rants on other threads and cannot believe he has the front to preach to us here when he is a self confessed loser:-bones699 - 27 Feb 2024 - 22:40:53 - 1672 of 1859 My AGL investment sucks my average share price is 40p current share price 12p its a basket case just like me! |
Posted at 06/2/2024 09:19 by arab3 Love this bb, share price plummet everyone disappears share price rise back they come! |
Posted at 30/10/2023 09:50 by xxproinvestorxx This month Bill turned 61 so I would presume retirement is something on his mind. Dest is his only appointment as a director, so it is logical to assume his 6.5M shares constitutes a large proportion of his net wealth. The only way for him to extract any value, would be to sell his shares. However, doing so on the open market would be devastating to the share price.Of course, he could be waiting for further value inflection points and the completion of Phase 3 trials for M3 and/or XF-73, however it will be several years before Dest reach commercialisation should P3 trials be successful. Additional funding is also likely to be required (depending upon XF-73 deal terms) and, currently, it is probable that this would come from share placements, albeit at considerably higher market cap and share price than present. Of course this is all speculation on my part, but I'd like to know others thoughts? |
Posted at 30/10/2023 09:21 by xxproinvestorxx I'm surprised at the slip back in share price last week but then this is the Aim market.One thing I find curious is that both Chris and Bill have transferred a large proportion of their shares to their spouses in the past month. Bills are particularly intriguing, with 2.3M shares transferred on the 4th Oct. Chis has only just joined the company so there is less weight behind his transfer as he transferred the share shortly after purchasing them. But this still raised the question - why have they both transferred such a large number of shares? And why now? The shares were not transferred (by Bill) prior to the M3 deal, or had much interaction with the share in the past two years. The only logical conclusion I can deduce is that it optimises and reduces their taxes. However, this would only be a consideration if they are a. expecting a significant uplift in the share price and b. expecting to exit soon. We know they are searching for a partner for XF-73, but could a full acquisition be on the cards? And if so what price would someone have to pay? The current climate is pretty dire for raising capital, and there has been a drop-off in pharma deals recently, but many large pharma companies are sitting on large cash stock-piles. In addition, Dest have a significant advantage and are de-risked compared with other small pharma companies listed on Aim - with M3 & XF-73 both Phase 3 ready, a partner and deal worth up to $570M + royalties for the former, and, cash runway into 2025. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
.png){kind=logo}
